Impact of improvement of sleep disturbance on symptoms and quality of life in patients with functional dyspepsia

Nakamura, Fumihiko; Kuribayashi, Shiko; Tanaka, Fumio; Kawami, Noriyuki; Fujiwara, Yasuhiro; Iwakiri, Katsuhiko; Kusano, Motoyasu; Uraoka, Toshio

doi:10.1186/s12876-021-01659-y

Cited by 13 publications

(5 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In patients with IBS, more waking episodes during sleep was predictive of more abdominal pain ( 38 ), GI distress, and worse quality of life but not bowel consistency or frequency ( 37 ). One study demonstrated that improving sleep quality using prescription sleep aids improved GI symptoms and quality of life in patients with functional dyspepsia ( 40 ). Poor sleep quality has been associated with increased nausea, fatigue, and abdominal pain in children and adolescents with disorders of gut brain interaction ( 41 ).…”

Section: Discussionmentioning

confidence: 99%

Scoping review: the social and emotional impacts of gastroparesis

Simons,

Cline

2024

Transl Gastroenterol Hepatol

View full text Add to dashboard Cite

Background Patients with gastroparesis experience severe gastrointestinal symptoms including nausea, vomiting, early satiety, excessive fullness and bloating that can have significant negative effects on their mood, relationship with food/eating, and overall quality of life. The aim of this review was to systematically explore the literature on the social and emotional burdens experienced by patients with gastroparesis. Methods PubMed and Google Scholar were used to identify potential articles for inclusion. The population of interest was those with abnormal gastric emptying. Studies were excluded if they focused on the effects of a particular treatment for gastroparesis. Thirty-one articles were included based on search criteria. Results Three themes emerged, including healthcare utilization and opioid use, relationship between gastroparesis and mental health, and the impact of gastroparesis on lifestyle factors including sleep, nutrition, and social engagement. Patients experience challenges from a perceived lack of understanding of medical providers and loved ones and difficult to manage symptoms. Symptom specific anxiety, underlying psychiatric history, and symptom severity are associated with distress around symptoms. Self-reported symptom severity and severity of gastric emptying are not highly correlated. Conclusions Patients with acute onset and gradually worsening of symptoms over time are likely at increased risk of distress related to their disease. Patients commonly experience isolation from their medical providers and in other social relationships. Treatments aimed not only at reducing the severity of symptoms but also helping patients with gastroparesis engage with the enjoyed aspects of life are essential in mitigating the social and emotional impacts of gastroparesis.

show abstract

Section: Discussionmentioning

confidence: 99%

Scoping review: the social and emotional impacts of gastroparesis

Simons,

Cline

2024

Transl Gastroenterol Hepatol

View full text Add to dashboard Cite

show abstract

“…Improvement of insomnia by the administration of sleep aids (eszopiclone, zolpidem, and suvorexant) resulted in improvement of gastrointestinal symptoms and quality of life in patients with FD. This effect may be related to pain modification [39].…”

Section: Discussionmentioning

confidence: 99%

Improved Sleep Affects Epigastric Pain in Functional Dyspepsia by Reducing the Levels of Inflammatory Mediators

Du,

Lin,

Xiao

et al. 2023

Dig Dis

View full text Add to dashboard Cite

Introduction: The pathogenesis of epigastric pain in functional dyspepsia (FD) is complex. The study aims to explore the effect of sleep improvement on this symptom. Methods: In total, 120 patients with FD-associated epigastric pain and insomnia were randomly divided into experimental and control groups using the envelope method. After applying the exclusion criteria, 107 patients were enrolled in the experimental (56 patients) and control (51 patients) groups. Insomnia was graded according to the Pittsburgh Sleep Quality Index (PSQI). In the experimental group, eszopiclone 3 mg, eszopiclone 3 mg + estazolam 1 mg, and eszopiclone 3 mg + estazolam 2 mg were given to patients with mild, moderate, and severe insomnia, respectively. In the control group, patients were given 1, 2, or 3 tablets of vitamin B complex. Patient sleep quality was monitored with Sleepthing. Epigastric pain was evaluated with a Numeric Rating Scale. The serum levels of IL-1β, IL-6, IL-8, and tumor necrosis factor-α (TNF-α) were measured by enzyme-linked immunosorbent assay. Pain scores, sleep parameters, and serum levels of inflammatory mediators were compared before and after treatment. Results: After treatment, the pain scores, sleep parameters, and TNF-α and IL-6 levels in the experimental group were significantly lower than those in the control group (p < 0.05). PSQI insomnia scores were significantly associated with pain scores, IL-6, and TNF-α (p < 0.05) but not in IL-8 and IL-1β levels (p > 0.05) among the three groups. Conclusions: Improving sleep with eszopiclone and/or estazolam alleviates FD-associated epigastric pain, possibly by inhibiting related downstream transmission pathways and reducing the release of inflammatory mediators.

show abstract

“…A relationship between functional dyspepsia and insomnia has also been suggested [37, 38]. Hypnotics were previously shown to attenuate dyspeptic symptoms [39]. However, the mechanisms responsible for the amelioration of functional dyspepsia have yet to be elucidated.…”

Section: Discussionmentioning

confidence: 99%

Lemborexant Attenuates Regurgitation without Worsening Objective Parameters on Reflux Monitoring in Patients with Gastroesophageal Reflux Disease and Insomnia: A Single-Arm Proof-of-Concept Study

et al. 2023

Self Cite

View full text Add to dashboard Cite

Introduction: Esophageal hypersensitivity is associated with gastroesophageal reflux disease (GERD). Since sleep disturbance causes esophageal hypersensitivity, hypnotics may ameliorate GERD. However, zolpidem prolongs esophageal acid clearance. Lemborexant is a new hypnotic with higher efficacy and fewer adverse events than zolpidem. Therefore, the present study investigated the effects of lemborexant on GERD. Methods: Patients with heartburn and/or regurgitation and insomnia who did not take acid suppressants or hypnotics in the last month were recruited. Symptom assessments using GerdQ and reflux monitoring were performed before and after a 28-day treatment with 5 mg lemborexant at bedtime. The primary outcome was a change in the total GerdQ score, excluding the score for insomnia. Secondary outcomes were changes in each GerdQ score and the following parameters on reflux monitoring: the acid exposure time (AET), number of reflux events (RE), acid clearance time (ACT), and post-reflux swallow-induced peristaltic wave (PSPW) index. Results: Sixteen patients (age 45.0 [33.3–56.0], 11 females [68.8%]) completed the intervention (1 patient did not tolerate the second reflux monitoring). The total GerdQ score, excluding the score for insomnia, did not significantly change (8.0 [6.0–9.0] before vs. 7.0 [6.3–9.0] after p = 0.16). GerdQ showed the significant attenuation of regurgitation (2.0 [2.0–3.0] vs. 1.0 [0–2.8] p = 0.0054) but not heartburn (2.5 [1.0–3.0] vs. 1.0 [0.3–2.0] p = 0.175). No significant differences were observed in AET, RE, ACT, or PSPW index before and after the intervention. Conclusion: Lemborexant attenuated regurgitation without the worsening of objective reflux parameters. A randomized placebo-controlled study is warranted in the future.

show abstract

Impact of improvement of sleep disturbance on symptoms and quality of life in patients with functional dyspepsia

Cited by 13 publications

References 67 publications

Scoping review: the social and emotional impacts of gastroparesis

Scoping review: the social and emotional impacts of gastroparesis

Improved Sleep Affects Epigastric Pain in Functional Dyspepsia by Reducing the Levels of Inflammatory Mediators

Lemborexant Attenuates Regurgitation without Worsening Objective Parameters on Reflux Monitoring in Patients with Gastroesophageal Reflux Disease and Insomnia: A Single-Arm Proof-of-Concept Study

Contact Info

Product

Resources

About